Asset Management One Co. Ltd. Sells 3,064 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Asset Management One Co. Ltd. lowered its stake in shares of Exact Sciences Co. (NASDAQ:EXAS) by 4.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 65,551 shares of the medical research company’s stock after selling 3,064 shares during the period. Asset Management One Co. Ltd.’s holdings in Exact Sciences were worth $3,772,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in EXAS. AMF Tjanstepension AB bought a new position in Exact Sciences during the third quarter worth about $724,000. Creative Planning raised its position in shares of Exact Sciences by 14.8% during the third quarter. Creative Planning now owns 38,060 shares of the medical research company’s stock worth $2,593,000 after purchasing an additional 4,906 shares during the period. Blue Trust Inc. raised its position in shares of Exact Sciences by 61.0% during the third quarter. Blue Trust Inc. now owns 5,220 shares of the medical research company’s stock worth $356,000 after purchasing an additional 1,978 shares during the period. Sequoia Financial Advisors LLC acquired a new stake in shares of Exact Sciences during the third quarter worth about $569,000. Finally, Signaturefd LLC raised its position in shares of Exact Sciences by 53.7% during the third quarter. Signaturefd LLC now owns 1,652 shares of the medical research company’s stock worth $113,000 after purchasing an additional 577 shares during the period. Institutional investors own 88.82% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on EXAS shares. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a research report on Monday, January 13th. The Goldman Sachs Group dropped their price target on Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Piper Sandler dropped their price target on Exact Sciences from $85.00 to $75.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. BTIG Research raised their price target on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Finally, Stifel Nicolaus dropped their price target on Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, Exact Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $72.76.

Exact Sciences Stock Up 1.7 %

NASDAQ:EXAS opened at $50.48 on Thursday. The stock’s 50 day moving average price is $55.41 and its two-hundred day moving average price is $60.10. The firm has a market capitalization of $9.34 billion, a price-to-earnings ratio of -43.14 and a beta of 1.24. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. Equities research analysts expect that Exact Sciences Co. will post -1.1 earnings per share for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.